Blood transfusion

WellSky® Joins Collaborative Effort to Improve Transfusion Safety Through National Alloantibody Exchange

Retrieved on: 
Tuesday, February 7, 2023
Cardiology, Software, Practice Management, Data Analytics, Health, Hospitals, Professional Services, Technology, Blood, Patient safety, LifeSouth Community Blood Centers, Hospital, Coombs test, Blood transfusion, Food, Antigen, Kansas City metropolitan area, Criticism of the Food and Drug Administration, Medical device, Blood product

WellSky , a leading health and community care technology company, today announced a collaborative effort with the Alloantibody Exchange , a non-profit dedicated to improving blood transfusion safety and building a national transfusion antibody registry easily accessible to both hospitals and blood banks.

Key Points: 
  • WellSky , a leading health and community care technology company, today announced a collaborative effort with the Alloantibody Exchange , a non-profit dedicated to improving blood transfusion safety and building a national transfusion antibody registry easily accessible to both hospitals and blood banks.
  • The Alloantibody Exchange works with technology partners like WellSky to facilitate access to red blood cell antibody information across hospital transfusion services.
  • “We started the Alloantibody Exchange because transfusion recipients were receiving incompatible blood, and it seemed largely preventable,” said Dr. George Hauser, president and founder of the Alloantibody Exchange.
  • The Alloantibody Exchange will provide WellSky clients with secure and near real-time access to this important data.”
    WellSky is joining 45 leading hospitals in recognition of the important blood transfusion safety benefits of the Alloantibody Exchange.

Butterfly Needles Market Report 2023: Advantages Over Straight Needles Drives Adoption - ResearchAndMarkets.com

Retrieved on: 
Monday, January 30, 2023
Medical Supplies, Health, US Census Bureau International Data Base, World Heart Federation, Blood, Cancer, Hospital, LDL, Vein, Patient, Needle, World Health Organization, Blood transfusion, Trauma, Diabetes, United States Census Bureau, Risk, IV, Application, WHO, Death, Stroke, Shock (mechanics), Survival, Plasma, Growth, Kent, Anti-transglutaminase antibodies, Conditional sentence, Prevalence, Chronic Respiratory Disease, COVID-19, Kidney, Vaccine, Pharmaceutical industry

The "Butterfly Needles Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Application and End User" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Butterfly Needles Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Application and End User" report has been added to ResearchAndMarkets.com's offering.
  • The growth of the global butterfly needles market is driven by the rise in the prevalence of chronic diseases and the advantages of butterfly needles over straight needles.
  • However, the risk associated with butterfly needles stick injuries is hampering the market growth.
  • Based on application, the butterfly needles market is categorized into blood collection, IV rehydration, delivery of medications, venipuncture, and blood transfusion.

Global Hepatitis C Testing Market Report to 2031 - Players Include Abbott Laboratories, BIO-RAD Laboratories, Cosara Diagnostics and Illumina - ResearchAndMarkets.com

Retrieved on: 
Monday, January 23, 2023
Infectious Diseases, Pharmaceutical, Health, Benchmarking, Viral, World Health Organization, PCR, Hepatitis C, Blood transfusion, Porter's five forces analysis, Test, HIV, WHO, Hepatitis, HCV, Syphilis, FDA, Growth, Prevalence, Liver, Infection, Hepatitis B, Pharmaceutical industry, Vaccine, Marketing

The global hepatitis C testing market was valued at $1,329.0 million in 2021, and is projected to reach $2,248.2 million by 2031, registering a CAGR of 5.3% from 2022 to 2031.

Key Points: 
  • The global hepatitis C testing market was valued at $1,329.0 million in 2021, and is projected to reach $2,248.2 million by 2031, registering a CAGR of 5.3% from 2022 to 2031.
  • The increasing rate of hepatitis C and rise in awareness about hepatitis C drives the growth of market.
  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hepatitis c testing market analysis from 2021 to 2031 to identify the prevailing hepatitis c testing market opportunities.
  • The report includes the analysis of the regional as well as global hepatitis c testing market trends, key players, market segments, application areas, and market growth strategies.

The Worldwide Hepatitis C Testing Industry is Projected to Reach $2.2 Billion by 2031 at a 5.3% CAGR

Retrieved on: 
Tuesday, January 24, 2023
NIB, Immunoassay, Hepatitis C, Liver, Infection, Viral, Hepatitis, National Institute for Biological Standards and Control, Hepatitis B, Blood, Illumina, Inc., PerkinElmer, PCR, ELISA, Syphilis, FDA, Porter's five forces analysis, Growth, Benchmarking, Prevalence, HCV, Abbott Laboratories, Laboratory, World Health Organization, WHO, Blood transfusion, Polymerase chain reaction, HIV, Thermo Fisher Scientific, Pharmaceutical industry, Vaccine, Marketing

The global hepatitis C testing market was valued at $1,329.0 million in 2021, and is projected to reach $2,248.2 million by 2031, registering a CAGR of 5.3% from 2022 to 2031.

Key Points: 
  • The global hepatitis C testing market was valued at $1,329.0 million in 2021, and is projected to reach $2,248.2 million by 2031, registering a CAGR of 5.3% from 2022 to 2031.
  • The increasing rate of hepatitis C and rise in awareness about hepatitis C drives the growth of market.
  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hepatitis c testing market analysis from 2021 to 2031 to identify the prevailing hepatitis c testing market opportunities.
  • The report includes the analysis of the regional as well as global hepatitis c testing market trends, key players, market segments, application areas, and market growth strategies.

New Study Evaluates the Performance of Masimo SpHb® Noninvasive Spot-Check Hemoglobin in the Emergency Department

Retrieved on: 
Monday, January 9, 2023
Health, Medical Devices, Hospitals, Health Technology, General Health, Clinical Trials, Biotechnology, Infection, Blood transfusion, Pain, American Journal, ED, Dar Al Uloom University, Research, Judgement, Multimedia, Emergency medicine, MASI, HB, Annals of Emergency Medicine, Patient, EDS, Unicel, Hospital, Collection, Bleeding, Medical imaging, Masimo

Hemoglobin was noninvasively measured (SpHb) using the Masimo Rad-67® handheld Pulse CO-Oximeter® with the DCI®-mini fingertip sensor.

Key Points: 
  • Hemoglobin was noninvasively measured (SpHb) using the Masimo Rad-67® handheld Pulse CO-Oximeter® with the DCI®-mini fingertip sensor.
  • The researchers found a “highly significant correlation” between SpHb and LabHb (Pearson correlation coefficient = 0.812, p
  • The researchers concluded that “noninvasive hemoglobin (SpHb) measurement showed acceptable accuracy and excellent correlation with LabHb and provided an easy, quick, feasible, cheap, and accurate solution for Hb measurement in the ED.
  • Further research is required to study its effects on patient outcomes and blood transfusion and time and cost effectiveness.”
    SpHb is not intended to replace laboratory blood testing.

Blood Community Unites to Thank America’s Donors this National Blood Donor Month

Retrieved on: 
Wednesday, January 4, 2023
Veteran, ABC, International Red Cross and Red Crescent Movement, Blood transfusion, Volunteering, Blood, Food, 2017 New Year Honours, Regulation of tobacco by the U.S. Food and Drug Administration, Transfusion medicine, Organization, Disaster, Red Cross, Accreditation, American Red Cross, AABB, Hospital, Life, Redcross, World Red Cross and Red Crescent Day, Medical device, Pharmaceutical industry

Washington, DC, Jan. 04, 2023 (GLOBE NEWSWIRE) -- America’s Blood Centers, the Association for the Advancement of Blood & Biotherapies (AABB), and the American Red Cross are joining together to thank America’s more than 7 million blood donors as they mark National Blood Donor Month.

Key Points: 
  • Washington, DC, Jan. 04, 2023 (GLOBE NEWSWIRE) -- America’s Blood Centers, the Association for the Advancement of Blood & Biotherapies (AABB), and the American Red Cross are joining together to thank America’s more than 7 million blood donors as they mark National Blood Donor Month.
  • This month recognizes America’s donors and encourages more people to give blood.
  • National Blood Donor Month is an opportunity to recognize the more than 7 people million who donate blood each year and encourage more people to become donors and help save lives,” said Kate Fry, chief executive officer at America’s Blood Centers.
  • “Here is a New Year's resolution we should all make: become a regular blood donor in 2023, and start now as we mark National Blood Donor Month,” said Debra BenAvram, chief executive officer of AABB.

New Prospective Study Evaluates the Accuracy of Masimo SpHb® Noninvasive and Continuous Hemoglobin Monitoring During Elective Cesarean Section

Retrieved on: 
Tuesday, January 3, 2023
Medical Devices, Health, Telemedicine, Virtual Medicine, Biometrics, Health Technology, General Health, Ageing, CS, Blood transfusion, Anesthesia, Injury, Cairo University, Judgement, Multimedia, MASI, Patient, Bleeding, Pregnancy, Particle-size distribution, Safety, Post-transfusion purpura, Bland–Altman plot, Medical device, HB

Masimo (NASDAQ: MASI) today announced the findings of a prospective study published in the Egyptian Journal of Anesthesia in which Dr. Mohamed Ibrahim Beleta and colleagues at Cairo University evaluated the accuracy of noninvasive, continuous hemoglobin monitoring with Masimo SpHb® on patients undergoing elective cesearan section (CS) with antepartum hemorrhage.

Key Points: 
  • Masimo (NASDAQ: MASI) today announced the findings of a prospective study published in the Egyptian Journal of Anesthesia in which Dr. Mohamed Ibrahim Beleta and colleagues at Cairo University evaluated the accuracy of noninvasive, continuous hemoglobin monitoring with Masimo SpHb® on patients undergoing elective cesearan section (CS) with antepartum hemorrhage.
  • During the procedure, all patients were monitored as per hospital standards, and in addition, with Masimo SpHb.
  • The investigators concluded, “Continuous SpHb Masimo Pulse CO-Oximetry shows an appropriate clinically reliable Hb calculation in comparison to Invasive Hb even in patients undergoing CS with low hemoglobin.
  • Clinical decisions regarding red blood cell transfusions should be based on the clinician’s judgment considering, among other factors, patient condition, continuous SpHb monitoring, and laboratory diagnostic tests using blood samples.

Forty Starving Sheep Saved from Backyard Slaughter Operation in New York's Hudson Valley

Retrieved on: 
Friday, December 16, 2022
Mother, Seizure, Assistant District Secretary of Chama Cha Mapinduzi, Sanctuary, Sheep, Blood transfusion, 99 Bottles of Beer, Magic, Animal, Anemia, Death, Animal rights, Law enforcement, HuffPost, Love, CAS, Safety, Health, SPCA, Quarantine, Farm Sanctuary, Milk, Whaling

SAUGERTIES, N.Y., Dec. 16, 2022 /PRNewswire/ -- In an extremely rare victory for farm animals, three New York organizations–an animal rescue organization, a law enforcement agency, and a district attorney's office–have secured the release of 40 starving sheep from a backyard slaughter operation.  As the rescued sheep heal, a Christmas "baby boom" is occurring as the sheep give birth to tiny lambs. Ten have been born to date.

Key Points: 
  • As the rescued sheep heal, a Christmas "baby boom" is occurring as the sheep give birth to tiny lambs.
  • Within days of their arrival, three sheep passed away, despite being given blood transfusion from healthy resident sheep.
  • Since the sheep have arrived, CAS is thrilled to announce the birth of ten tiny lambsjust in time for Christmas.
  • Founded in 2001, Catskill Animal Sanctuary is a non-profit, 150-acre refuge in New York's Hudson Valley.

70,000 "We Are One" Volunteers Participate in the Largest Group Blood Donation in History

Retrieved on: 
Monday, December 5, 2022
Multimedia, New York Blood Center, Blood, Health, Patient, Shincheonji Church of Jesus, Volunteering, COVID-19, Blood transfusion, Pharmaceutical industry, Medical device, Online shopping

NEW YORK, Dec. 5, 2022 /PRNewswire/ -- The youth volunteer group We Are One had the goal of donating blood to 70,000 people from August 27th to November 27th. During the campaign, a total of 73,807 people completed blood donations over a period of 85 days. A total of 100,360 people participated in the largest group blood donation ever recorded.The blood supply lately has been low for reasons such as decreased participation in blood donations amid the prolonged COVID-19 pandemic. With the goal of completing 70,000 blood donations by November to prepare for the winter season — along with the upcoming holidays when the blood supply is usually reduced — We Are One members actively donated blood.The campaign was conducted at blood banks in 17 metropolitan areas across South Korea and as planned, 70,000 blood donations were completed by November 27th.In order for a large number of people to donate blood in a short period of time, We Are One focused on coordinating individual schedules based on the needs of the blood banks. Volunteers made efforts to maintain their own health and ensure they would not be disqualified or prevented from donating blood. In order to reach the goal of achieving 70,000 blood donations before winter, about 100,000 We Are One members visited blood banks and joined the campaign.Junsu Hong, a representative of We Are One, said, "Blood donation is the only means to save the lives of patients who need blood transfusion and is a noble volunteer work. I appreciate all the members who participated in the blood donation with a clear sense of calling for the practice of sharing life. We Are One will continue to participate in blood donation to overcome the blood supply shortage and strengthen the community safety net."We Are One was launched on July 30th as a volunteer group composed of youth members from Shincheonji Church of Jesus located in Korea and overseas. Volunteers in areas such as New York have also actively donated blood in recent months, even receiving recognition from the New York Blood Center.This press release was issued through 24-7PressRelease.com. For further information, visit http://www.24-7pressrelease.com.

Key Points: 
  • A total of 100,360 people participated in the largest group blood donation ever recorded.
  • The blood supply lately has been low for reasons such as decreased participation in blood donations amid the prolonged COVID-19 pandemic.
  • The campaign was conducted at blood banks in 17 metropolitan areas across South Korea and as planned, 70,000 blood donations were completed by November 27th.
  • We Are One will continue to participate in blood donation to overcome the blood supply shortage and strengthen the community safety net."

ESO Releases 2022 ESO Trauma Index to Explore Key Trends and Measures Affecting Trauma Centers Across the Country

Retrieved on: 
Thursday, November 17, 2022
Data Management, Health, Technology, Hospitals, Health Technology, Software, General Health, Hospital, ICU, Trauma, Hip, Intubation, Delirium, ESO, CPR, Injury Severity Score, Burn, Emergency medical services, Death, PRBC, Research, Safety, Data, Injury, Blood transfusion, EHR, HDE, Mortality, Cardiac arrest, Gq alpha subunit, ISS, EMS, Survival rate, Patient, Red blood cell, Blood product, Dentistry, Index

ESO , the leading data and software company serving emergency medical services (EMS), fire departments, hospitals, state and federal agencies, today announced the findings of its 2022 ESO Trauma Index , a report focused on key trends across hospital trauma programs nationwide.

Key Points: 
  • ESO , the leading data and software company serving emergency medical services (EMS), fire departments, hospitals, state and federal agencies, today announced the findings of its 2022 ESO Trauma Index , a report focused on key trends across hospital trauma programs nationwide.
  • The dataset for the ESO Trauma Index is from the ESO Data Collaborative .
  • The 2022 ESO Trauma Index looks at 884,456 deidentified patient records with hospital admission dates between January 1 December 31, 2021.
  • ESO (ESO Solutions, Inc.) is dedicated to improving community health and safety through the power of data.